Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Latest Information Update: 12 Jul 2024
At a glance
- Drugs MCLA 129 (Primary) ; Osimertinib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Merus
- 04 Jun 2024 Preliminary data (n=15) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 03 Jun 2024 According to a Merus media release, data from this trial presented at the 2024 American Society of Clinical Oncology (ASCO)
- 03 Jun 2024 Results published in the Merus Media Release